21st Annual Rx Drug Pricing Boot Camp -DS

21st Annual

BOOT CAMP

May 4–5, 2023

New York City Bar Association

New York, NY

Intensive training in the essentials and complexities of pricing calculations, rebates, and reporting under the Medicaid, Medicare, and PHS 340B Programs

A leading faculty of experienced practitioners will help you master core drug pricing concepts and calculations, and help you:

Angle-Right DECIPHER the complexities of the Inflation Reduction Act

Angle-Right UNDERSTAND how price is established and how the rebate system works

Angle-Right BUILD a live glossary of Medicaid and Medicare terminology

Angle-Right COMPREHEND the mechanics of Medicare Part B and D

Angle-Right DEVELOP a thorough understanding of different pricing benchmarks and calculations including AWP, AMP, BP and much more

Angle-Right UNDERSTAND the nuances of pricing and reimbursement under the Public Health Service 340B Program

Angle-Right DETERMINE appropriate coding, coverage, and reimbursement for new products

Distinguished Co-Chairs: Tiffany Frankson Assistant General Counsel, Pricing and Access Pfizer

Trevor Wear Partner

Sidley Austin LLP

Exclusive Fireside Chat: James Stansel Executive Vice President and General Counsel

PhRMA

ATTEND the Pre-Conference and Post-Conference Workshops to enhance your understanding of key concepts and the latest trends in biopharmaceutical pricing and rebates:

MAY 3, 2023

WORKSHOP A Government Payor Program

101: Primer on the Pricing Essentials of the Medicare, Medicaid, and PHS 340B Program

WORKSHOP B Inflation Reduction Act

Boot Camp: An In-Depth Review of Changes to Medicare Pricing under the IRA

MAY 5, 2023

WORKSHOP C Understanding the Big Picture: Connecting the Dots Between Government Payor Programs

Get Your All Access Pass to Include All Workshops!

Withboth federal and state law makers engaging in greater scrutiny of prescription drug pricing, now is the time when industry professionals must stay up to date on the latest amendments to government payor programs as well as their impact on the private sector. Join us to gain a holistic view of how these government payor programs relate and often intersect with each other.

Who Will You Meet?

PHARMACEUTICAL COMPANIES

• Corporate Counsel/General Counsel

• Vice Presidents, Officers, Directors and Managers for:

- Pricing, Pricing Strategy, Pricing Analytics

- Contracts and Reimbursement

- Managed Care

- Government Programs

- Medicaid/Medicare Rebates

- Finance/Accounting/Audit

- Government Affairs

The Inflation Reduction Act of 2022 Shifted the World

of Government Payor Programs and Raises a Host of Anticipated Questions for Rx Drug Pricing and Rebates

The implementation of IRA which began earlier this year and has significantly impacted Medicare, while posing indirect affects to the other government payor programs. Attend this event and understand the new provisions under the IRA. Explore and learn about the drug pricing negotiation program, dynamic changes Medicare Part D standard discounts, Part B reimbursements for biosimilars, and related new concerns with the Anti-Kickback statute.

Understand the Essentials to Pricing, Negotiations, and Rebates under Medicare Part B and D

Medicare has evolved significantly, leaving many professionals questioning the process of pricing, negotiations, and rebates within this realm. We will examine how to negotiate maximum fair price under Part B and D, streamline inflation rebate penalties under Part B and D as well as explore the provisions of the Drug Wastage Rule.

Explore New Developments and Impacts of the PHS 340B Program

Recent updates to the 340B program have added to the urgency of pricing and coverage will look. Join us as we take a deep dive into this evolving government payor program as leading professionals discuss how to calculate pricing under 340B, while defining and redefining 340B entities and who qualifies. We will provide an in-depth look into the new 340B ADR rule and will help you form strategies to address the limiting scope of the ADR timeline process.

Obtain a Thorough Understanding of All Complexities Under Medicaid Drug Pricing and Rebates

The provisions and analysis under Medicaid can often lead to confusion and improper calculations that pose severe consequences on professionals and companies involved. We will examine the formulas and correct calculations needed for drug pricing and rebates, while highlighting the difference between brand drugs versus generic drugs. While adding to your living glossary list of Medicaid terminology, learn about the indirect impacts the IRA has on Medicaid.

Register today for the most comprehensive “how to” Rx Drug Pricing conference, where top minds convene to network and engage in thought-provoking discussions as well as provide practical advice for engaging in the pricing and rebate process.

- Marketing

• Compliance Officers

LAW FIRMS

• Attorneys with practice areas in:

- Pharmaceuticals

- Healthcare

- Food and Drug

PBMS

• Corporate Counsel/General Counsel

• Vice Presidents, Officers, Directors and Managers for:

- Contract Management

- Network Pharmacy

- Retail Pharmacy Operations

- Government Programs

- Pricing and Operations

- Clinical Operations

- Industry Relations/Government Affairs

• Financial Analysts

PHARMACIES

• Corporate Counsel/General Counsel

• Vice Presidents, Officers, Directors and Managers for:

- Pricing

- Business Development

PLANS

• Corporate Counsel/General Counsel

• Vice Presidents, Officers, Directors and Managers for:

- Pharmacy Networks

- Pharmaceutical Contracting

- Clinical

- Pharmacy Services

American Conference Institute (ACI) is pleased to announce that the 21st Annual Rx Drug Pricing Boot Camp will be back in-person in New York City on May 4–5, 2023.

Distinguished Faculty

Co-Chairs:

Tiffany Frankson Assistant General Counsel, Pricing and Access Pfizer

Trevor Wear Partner

Sidley Austin LLP

Esteemed Speakers:

Craig Bleifer Partner

Akin Gump Strauss Hauer & Feld LLP

Merle DeLancey Jr. Partner Blank Rome LLP

Greg Fersko Managing Consultant H & LS Consulting

Stephen Forster Contracting & Government Pricing Otsuka

Margaux Hall Partner

Ropes & Gray LLP

Stacie Heller Senior Policy Director Crowell & Moring LLP

Christopher Jackson Managing Member The Law Office of Christopher S. Jackson, LLC

Brett Kelly Senior Director, Contract Operations and Pricing Strategy Vifor Pharma

Dennis Kim Senior Engagement Manager Syneos Health Consulting

Liz Lindquist Partner Arnold & Porter LLP

Ross Margulies Partner Foley Hoag LLP

Juliet McBride Partner King & Spalding LLP

Joseph Metro Partner Reed Smith LLP

Rick Moore Managing Partner Federal Compliance Solutions

Daniel Moynihan General Counsel Ono Pharma USA

Kathleen Peterson Counsel Hogan Lovells LLP

Linda Reig Partner Buchanan Ingersoll Rooney LLP

Kathy Roe Managing Attorney & Co-Founder Health Law Consultancy

Global Sponsorship Opportunities

With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, The Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.

Don’t miss the opportunity to maximize participation or showcase your organization’s services and talent. For more information please contact us at: SponsorInfo@AmericanConference.com

Andrew Ruskin Partner K & L Gates LLP

David Sandoval Chief Legal Officer Leadiant Biosciences

Chris Schott Partner Latham & Watkins LLP

James Shehan Senior Counsel Lowenstein Sandler LLP

James Stansel

Executive Vice President and General Counsel PhRMA

Stephanie Trunk Partner Arent Fox Schiff LLP

Sara Vann Assistant Attorney General Office of the Attorney General Chris Carr, Medicaid Fraud Division

Judith Waltz Partner Foley & Lardner LLP

Elaina Werner Corporate Counsel, Market Access Incyte Corporation

Constance Wilkinson Board of Directors/Member of the Firm

Epstein Becker & Green, P.C.

Pre-Conference Workshops

WEDNESDAY, MAY 3, 2023

WORKSHOP A 9:00am–12:30pm (Registration starts at 8:30am)

Government Payor Program 101: Primer on the Pricing Essentials of the Medicare, Medicaid, and PHS 340B Program

microphone-alt Joseph Metro, Partner, Reed Smith LLP

James Shehan, Senior Counsel, Lowenstein Sandler LLP

Join us for this primer on the fundamentals of pharmaceutical pricing related to government payor programs and obtain an in-depth working knowledge of these programs which will lay the foundation for the more in-depth discussions that will take place throughout the main conference. Points of discussion will include:

• Reviewing applicable legislation such as the IRA, MMA, DRA, ACA, and recently enacted IRA and key agency rules/guidance

• Tracking the flow of payments and reimbursements in the health care supply chain

» Identifying stakeholders within the chain and their roles

» Tracking the flow of drugs, payments, and services

• Deciphering commonly used acronyms and terminology

• Surveying the different pricing benchmarks and calculations

» AWP, WAC, AMP, BP, URA, ASP, PHS, non-FAMP, and FCP

• Understanding the implications of different pricing methodologies, calculations, and benchmarks for different stakeholders

• Examining the key pricing concepts and calculations for government drug pricing and rebate programs

» Medicaid Drug Rebate program

» Medicare Part B and D

» 340B Drug Pricing program

» Federal Supply Schedule/Federal Ceiling Price

» TRICARE

• Considering the interactions among the programs

• Understanding how participation in the Medicaid Drug Rebate Program impacts participation in the PHS 340B program

12:30pm-1:30pm Light Lunch and Networking Break

Due to their hands-on nature, workshops are only available in-person.

WORKSHOP B 1:30pm–5:00pm (Registration to begin at 1:00pm)

Inflation Reduction Act Boot Camp: An In-Depth Review of Changes to Medicare Pricing under the IRA

microphone-alt Dennis Kim, Senior Engagement Manager, Syneos Health Consulting

Stacie Heller, Senior Policy Director, Crowell & Moring LLP

Margaux Hall, Partner, Ropes & Gray LLP

The Inflation Reduction Act marked a monumental shift in Medicare and to some extent Medicaid drug pricing policy. The drug pricing provisions set out in the IRA are complex and include a slate of new obligations and considerations for pharmaceutical manufacturers, most notably mandatory pricing negotiations on the costliest drugs. This workshop will provide a timely analysis of drug pricing provisions under the IRA as well as current and projected impacts on drug manufacturers and the pharmaceutical industry at large. Key points of discussion include:

• Break down the Inflation Reduction Act

» Determining the impact of IRA on Medicare drug pricing

» Examining concerns from Medicaid and dual-eligible

• Understanding CMS’s negotiation of maximum fair prices under Medicare Parts B and D

• Examining Inflation rebates payable under Part B and D

• Analysis of Part D re-design, including new manufacturer discounts

• Examining what has currently been implemented under the IRA

• Anticipating what’s ahead and what will be implemented

• Dissecting the misconceptions of the IRA

• Examining key provisions in the IRA for manufacturers to consider

» Identifying what drugs will be subject to negotiation

» Negotiation timelines and process

» Enforcement provisions

• Analysis of the implications for drug manufacturers

» Examining how the negotiation provisions will impact product prices

- Maximum fair price calculations

» Understanding the mechanics of inflation rebate calculations for Medicare Part B and D

• Understanding of how drug pricing reforms will be applied in the real word through hypothetical examples

Main Conference Day One

THURSDAY, MAY 4, 2023

7:30am Continental Networking Breakfast and Registration

8:15am

Co-Chair’ Welcome Remarks

microphone-alt Tiffany Frankson, Assistant General Counsel, Pricing and Access, Pfizer

Trevor Wear, Partner, Sidley Austin LLP

8:30am

Fireside Chat with PhRMA

microphone-alt James Stansel, Executive Vice President and General Counsel, PhRMA

Trevor Wear, Partner, Sidley Austin LLP

Join us for this highly anticipated discussion with Jim Stansel of PhRMA on the far-reaching policy implications of the Inflation Reduction Act. Come prepared with your most pressing questions as we will also allot time for Q&A.

FOCUS ON PRICING AND REBATE CHANGES UNDER IRA

9:15am

Demystifying the Inflation Reduction Act of 2022: An In-Depth Examination and Clarification of the IRA’s Impact on Medicare and Medicaid Drug Pricing

microphone-alt Tiffany Frankson, Assistant General Counsel, Pricing and Access, Pfizer

Joseph Metro, Partner, Reed Smith LLP

• Analyzing key provisions of the IRA which directly affect Medicare and Medicaid Drug Pricing

• Examining pricing provisions which went into effect on January 1, 2023

• Identifying which drugs so far have been affected by IRA provisions

10:15am Morning Coffee Break

10:30am

Anticipating the Next Part of IRA Drug Pricing Implementation

microphone-alt Greg Fersko, Managing Consultant, H & LS Consulting

• Anticipating new HHS and CMS rulemaking relative to IRA implementation

» What are they implementing next?

» What will the process be?

• Forecasting applicable guidance and rulemaking relative to:

» Selected Drug List – Part D

» CMS Negotiation Agreement

» Submission of Manufacturer Data to CMS

11:15am

A Cautionary Tale: The Unintended Consequences of the Inflation Reduction Act

microphone-alt Craig Bleifer, Partner, Akin Gump Strauss Hauer & Feld LLP

Brett Kelly, Senior Director, Contract Operations and Pricing Strategy, Vifor Pharma

• Understanding how drug distribution will be affected by the IRA

• Anticipating how the IRA will impact Federal healthcare programs other than Medicare

• Forecasting if the IRA’s intended consequence of lower Medicare drug prices will come to fruition

• Examining how the IRA will impact State drug pricing programs under Medicaid

• Comprehending how competitors whose drugs do not make the selected drugs list under the IRA will be affected

» Anti-competitive affect

» Biosimilars exception

12:00pm Networking Luncheon

1:00pm

What Pricing Counsel and Executives Need to Know About the Medicare Part B Drug Wastage Rule

microphone-alt Judith Waltz, Partner, Foley & Lardner LLP

• Analyzing the Medicare Part B Drug Wastage Rule

• Understanding manufacturer requirements for discarded drug units and related protocols

• Breaking down the mechanics of the refund calculation and a manufacturer’s ability to dispute

• Analyzing the circumstances leading to a drug receiving an increased amount of permitted wastage

• Examining the implementation timeline of the rule and refund payments

• Exploring the interplay between the IRA and the Drug Wastage Rule

2:00pm

How to Negotiate the Maximum Fair Price Under Medicare Part B and D

microphone-alt Margaux Hall, Partner, Ropes & Gray LLP

• Identifying selected drugs which will fall under the maximum fair price requirement category

• Analyzing the fair pricing requirement

• Detailing the HHS negotiation process and timeline

• Understanding the significance of the shift in responsibility to identify MFP

• Calculating maximum fair pricing and why it is important to the negotiation requirement

2:45pm

Simplifying Inflation Rebate Penalties Under Medicare Part B and D

microphone-alt Kathleen Peterson, Counsel, Hogan Lovells LLP

Kathy Roe, Managing Attorney & Co-Founder, Health Law Consultancy

• Understanding IRA inflation rebate requirements for Part B drugs and its relationship to ASP

• Examining the IRA inflation rebate requirement for Part D drugs and its relationship to AMP

• Analyzing the benchwork periods for evaluating inflation for both existing and new drugs

• Evaluating what utilization is and is not subject to the rebate requirements

• Working through the mechanics of precisely how the rebates are calculated

• Exploring penalties for manufacturers who do not comply with new rebate provisions

• Looking at the impact and interplay of the IRA inflation rebates on commercial sales

3:45pm Afternoon Refreshment Break

MEDICIAD PRICING ESSENTIALS

Main Conference Day Two

FRIDAY, MAY 5, 2023

7:30am Continental Breakfast and Registration

8:15am

Co-Chair’ Opening Remarks and Recap of Day 1

microphone-alt Tiffany Frankson, Assistant General Counsel, Pricing and Access, Pfizer

4:00pm

Eliciting the Importance of WAC and AWP

microphone-alt Stephanie Trunk, Partner, Arent Fox Schiff LLP

• Understanding how AWP is calculated

» When is AWP still used?

• Discovering how Wholesale Average Cost is set?

» When is WAC used?

• Defining the relationship between WAC and AWP

» Why are these relevant?

• Understanding the relationship between actual sales prices and WAC and AWP

• Exploring the roles of AWP and WAC in calculating rebates

4:45pm

An In-Depth Illustration of Medicaid Drug Pricing and Rebates

microphone-alt Christopher Jackson, Managing Member, The Law Office of Christopher S. Jackson, LLC

Chris Schott, Partner, Latham & Watkins LLP

• Exploring the components of Medicaid’s drug rebate system

» Defining AMP

» What is “Best Price”?

• Outlining the formulas needed to determine unit rebate amounts

» Unit rebate amount for brand drugs

» Unit rebate amount for generic drugs

• Understanding the impact of price increases on unit rebate mounts

» What is the baseline period for brand drugs

» What is the baseline period for generic drugs

• Identifying line extensions and their impact on unit rebate amounts

• Dissecting manufacturer reporting requirements

» What are the best practices?

• What are the downstream effects on AMP, Best Price, and unit rebate amounts

• Answering how the IRA impacts Medicaid indirectly (dual-eligible)

5:45pm

Closing Remarks – Day 1 Adjourns

About us:

Trevor Wear, Partner, Sidley Austin LLP

8:30am

FOCUS ON PHS340B

Exploring New Developments Affecting the PHS 340B Program

microphone-alt Stephen Forster, Contracting & Government Pricing, Otsuka

Trevor Wear, Partner, Sidley Austin LLP

• Examining the evolution of the PHS 340B program and recent developments

» Understanding how 340B pricing is calculated

» Defining and redefining 340B entities

• Navigating the complexities of determining who qualifies for 340B

• Analyzing specific state 340B legislation

• Examining the new 340B ADR rule

» Outlining the limitations on the scope of what can be addressed through the ADR process

» Timeline/Timeframe changes

9:30am

The Seismic Impact of Recent Case Law on the 340B Program

microphone-alt Constance Wilkinson, Board of Directors, Member of Team, Epstein Becker Green LLP

Ross Margulies, Partner, Foley Hoag LLP

Elaina Werner, Corporate Counsel, Market Access, Incyte Corporation

• Exploring recent case law and its effect on the 340B program

• Reimbursement reductions: American Hospital Association v. Becerra

• Contract pharmacies: Numerous Manufacturers v. Becerra

» Related state legislation: Arkansas

• Patient definition: Genesis Healthcare, Inc. v. Azar

For over 35 years, C5 Group has proVided the opportunities that bring together business leaders, professionals and international experts from around the world to learn, meet, network and make the contacts that create the opportunities. Our conferences and related products connect the power of people with the power of information, a powerful combination for business growth and success.

The C5 Group, comprising American Conference Institute, The Canadian Institute and C5 in Europe, is a leading global events and business intelligence company.

10:30am

Survey and Analysis of Present and Pending State Drug Transparency Laws

microphone-alt Linda Reig, Partner, Buchanan Ingersoll Rooney LLP

David Sandoval, Chief Legal Officer, Leadiant Biosciences

State price transparency laws continue to increase in number, breadth, and enforcement across the country. This session will look at:

• Understanding state drug price transparency reporting

• Addressing challenges with, and finding solutions for, reporting under non-uniform and sometimes conflicting state laws

» Trying to maintain consistent treatment across states

» When and how to seek trade secret protection

• Keeping up to date on current developments when they are often issued in the form of sub-regulatory/informal guidance

• Reviewing recent developments:

» States continuing to implement new programs

» States with programs in effect expanding and modifying reporting requirements

» States ramping up enforcement efforts

» More states establishing affordability boards

11:30am Morning Refreshment Break

11:45am

A Manufacturer’s Guide to Critical Drug Pricing and Reimbursement Considerations for New Products

microphone-alt Andrew Ruskin, Partner, K & L Gates LLP

Liz Lindquist, Partner, Arnold & Porter LLP

Daniel Moynihan, General Counsel, Ono Pharma USA

• Examining pricing and reimbursement considerations form the pre-commercialization through product launch stages

• Analyzing the procedural approaches to set a launch price for a new drug

• Understanding legal, policy, and reputational risks around price setting

• Ensuring transparency for the pricing process

• Considering the role of traditional and non-traditional functions in setting price

• Accessing government and commercial programs to secure appropriate coding, coverage, and reimbursement for new products

• Examining how the IRA is impacting the pricing of new products

12:45pm

Understanding Fraud and Abuse Control as Affected by New Provisions Under Government Drug Payor Programs

microphone-alt Merle DeLancey Jr., Partner, Blank Rome LLP

Juliet McBride, Partner, King & Spalding LLP

Sara Vann, Assistant Attorney General, Office of the Attorney General Chris Carr, Medicaid Fraud Division

• Identifying the increase in fraud in connection to government drug payor programs

» Examining recent instances of drug pricing fraud and abuse

• Understanding disclosures and points of investigation

» Renewed sense of coordination between the OIG and DOJ

• Reviewing best practices to minimize fraud

1:45pm

Closing Remarks – Main Conference Adjourns

Post-Conference Workshop

FRIDAY, MAY 5, 2023

WORKSHOP C 2:15pm–5:15pm (Registration starts at 1:45pm)

Understanding the Big Picture: Connecting the Dots Between Government Payor Programs

microphone-alt Rick Moore, Managing Partner, Federal Compliance Solutions

Christopher Jackson, Managing Member, The Law Office of Christopher S. Jackson LLC

Understanding how government drug price reporting programs affect each other as well as the consequences of new provisions that may benefit or limit all government programs is a critical competency. This workshop will provide a detailed overview of how each government price reporting program operates, how everything is linked together, and what are the critical variables. Key points of discussion include:

• What is the relevant role of each government payor program, and how does it operate (similarly or differently from the other programs)

• Why is so much attention paid to the Medicaid program (even if utilization is low for a drug)

• How does a change in the Medicaid program affect the rest of the programs

• Where are the pain points in each of the government payor program

• Where are the government programs more or less rigid, and how to operate where there is no applicable guidance

• What is the relationship between commercial sales and the government programs

• How will the IRA affect the legacy price reporting calculations (e.g., ASP, AMP/BP, 340B, non-FAMP/FCP)

• And, much more

Venue & Accommodation

VENUE: New York City Bar Association

ADDRESS: 42 West, 44th Street, New York, NY 10036-6689

ACCOMMODATIONS: Sofitel New York Hotel

ADDRESS: 45 West, 44th Street, New York, NY

RESERVATIONS: 1-212-782-3015

American Conference Institute is pleased to offer our delegates a limited number of hotel rooms at a negotiated rate. To take advantage of these rates, please contact the hotel directly and quote “ACI”

Continuing Legal Education Credits

EARN CLE CREDITS

Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as nontransitional for the purposes of CLE accreditation.

ACI certifies this activity has been approved for CLE credit by the New York State Continuing Legal Education Board.

ACI certifies this activity has been approved for CLE credit by the State Bar of California.

ACI has a dedicated team which processes requests for state approval. Please note that event accreditation varies by state and ACI will make every effort to process your request.

For more information on ACI’s CLE process, visit: www.AmericanConference.com/Accreditation/CLE

Continuing Professional Education Credits

American Conference Institute is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of Continuing Professional Education (CPE) on the National Registry of CPE Sponsors. State Boards of Accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be submitted to the National Registry of CPE Sponsors through its website: www.nasbaregistry.org

Course Objective:

Essential training and timely updates on Medicare, Medicaid, and PHS 340B programs

• Medicare and Medicaid Pricing Fundamentals: Key Terminology and Essential Calculations for an Evolving Payor Market

• Planning for Drug Launch, Distribution, and Commercial Contracting: A Focus on Service Fees & Related Government Pricing Considerations

• Co-Pay Coupons, Accelerators, and Maximizers: Examining the Impact on Medicare and Medicaid Pricing

• Critical Drug Pricing and Reimbursement Considerations for Manufacturers: From Pre-Commercialization to Product Launch

There are no pre-requisites and advance preparation is not required to attend this conference.

Field of Study: Business Law

Email: education@americanconference.com for breakdown by credit

Prerequisite: None

Level of knowledge: Basic

Advanced Preparation: None

WHO SHOULD ATTEND:

CFO, General Counsel, VP or Director Government Compliance, VP or Director Finance, VP or Director Contracts, Procurement, Cost Accounting, Accounting Firms

TEACHING METHOD: Group Live and Group Internet Based

DELIVERY METHOD: Group Live and Group Internet Based

Participants will earn up to 13 CPE credits for the main conference and 3 credits for the each for the pre and post-conference workshops.

Group Internet Based Participants, please note: To be awarded full credits, you must actively participate in activities (such as polling) and submit the verification codes presented in the chat. For more information and to submit your CPE request visit: https://www.americanconference.com/accreditation-instructions-for-virtual-attendance/#CPE.

Refunds and Cancellations: Requests for credit memos or refunds must be received in writing by April 29, 2023 and will be subject to a cancellation fee. No refunds will be granted after April 29, 2023.

For more information regarding refund, complaint, and/or program cancellation policies please contact our offices at 1-888-224-2480.

If you or someone in your organization wants to attend both Rx Drug Pricing and "Big Four" Pharmaceutical Pricing happening the same week in New York – receive 10% OFF YOUR REGISTRATION to "Big Four" when you add this to your Rx Drug Pricing registration.

If you register a group from the same company to both events, save even more.

Book with Confidence!

WORRY FREE Registration GUARANTEE

Register and pay to lock in your early rate and be eligible for a full refund until April 17, 2023.

If you are unable to attend for any reason, you will have the following options:

y A full credit note for you, or a colleague to attend another event.

y A full refund.

Distinguished Co-Chairs: Trevor Wear Partner Sidley Austin LLP May 1 – 2, 2023 New York, NY LEARN MORE Mark Parrish, American Conference Institute M.Parrish@AmericanConference.com 1 212 352 3220 x7207 Use Registration Code: B00-999-MPH23   Dan Manganiello, American Conference Institute D.Manganiello@AmericanConference.com 1 212 352 3220 x5464 Use Registration Code: B00-999-DMO23   Looking to Register? Contact our Customer Service Representatives:

SAVE

All program participants will receive an online link to access the conference materials as part of their registration fee. Additional copies of the Conference Materials available for $199 per copy.

To update your contact information and preferences, please visit

Terms & conditions and refund/cancellation policies can be found at

PLEASE NOTE THE FOLLOWING PANDEMIC-RELATED PROTOCOLS:

ACI conferences and events will be organized in accordance with the latest health and safety regulations, guidelines, and recommendations, directed by the CDC and local government authorities. Attendees are advised to consider their personal health needs.

Special

please

Attendees are asked to self-screen in the days leading up to, before and after attending an ACI event and/or conference.